Corbus Pharmaceuticals Holdings, Inc. priced a new underwritten public offering of 4,744,231 shares of common stock at $13.00 per share, accompanied by pre‑funded warrants to purchase 1,025,000 shares at $12.9999 each, for an approximate gross offering size of $75 million.
The offering is led by Jefferies, with RBC Capital Markets, LifeSci Capital, and Mizuho Securities as co‑managers. The transaction is expected to close on or about November 3, 2025. Net proceeds will fund clinical development of the company’s oncology and obesity programs, support working capital, and meet other general corporate purposes.
Prior to the offering, Corbus reported $147 million in cash and investments as of June 30 2024, $149.1 million as of December 31 2024, and an expected $104 million as of September 30 2025. The new capital is intended to extend the company’s cash runway beyond Q3 2027, allowing continued investment in key pipeline candidates such as CRB‑701, an antibody‑drug conjugate targeting Nectin‑4, CRB‑601, an anti‑integrin monoclonal antibody, and CRB‑913, a CB1 inverse agonist for obesity.
Management emphasized that the offering strengthens Corbus’s financial position and supports the company’s strategy to advance its oncology and obesity programs through critical development milestones. The company’s leadership highlighted the competitive landscape of targeted therapies and the growing opportunity in obesity treatment, underscoring the importance of securing sufficient funding to maintain progress in these areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.